{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:54:17Z","timestamp":1760298857654},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,12,27]],"date-time":"2013-12-27T00:00:00Z","timestamp":1388102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"National Cancer Center Research and Development Fund","award":["23-A-18"],"award-info":[{"award-number":["23-A-18"]}]},{"name":"Ministry of Health, Labour, and Welfare of Japan"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Few articles have been published on the imaging findings of anaplastic lymphoma kinase (<jats:italic><jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content><\/jats:italic>)\u2010positive non\u2010small\u2010cell lung cancer (<jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content>). To investigate the radiological findings of <jats:italic><jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content><\/jats:italic>\u2010positive <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content> in the advanced stage, <jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content> scans were examined. In addition, the response to chemotherapy was evaluated. Of the 36 patients with <jats:italic><jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content><\/jats:italic>\u2010rearranged <jats:styled-content style=\"fixed-case\">NSCLC<\/jats:styled-content>, a mass and a nodule were identified in 17 (47.2%) and 16 (44.4%), respectively, indicating that more than 40% had a small\u2010sized tumor. Overall, 31 (86.1%) patients had lymphadenopathy, seven (19.4%) had extranodal lymph node invasion, and three (8.3%) had lymphangitis. A pleural effusion was seen in 15 patients (41.7%). All but one patient had no ground\u2010glass opacity (<jats:styled-content style=\"fixed-case\">GGO<\/jats:styled-content>) lesions, indicating that most <jats:italic><jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content><\/jats:italic>\u2010positive tumors showed a solid growth pattern without <jats:styled-content style=\"fixed-case\">GGO<\/jats:styled-content> on <jats:styled-content style=\"fixed-case\">CT<\/jats:styled-content>. Twenty were evaluable for response to chemotherapy; 10 (50.0%) had a partial response (<jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>), nine (45.0%) had stable disease (<jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>), and one (5.0%) had progressive disease (<jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>) with first\u2010line chemotherapy. With second\u2010line chemotherapy, five (26.3%) had <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content>, 11 (57.9%) had <jats:styled-content style=\"fixed-case\">SD<\/jats:styled-content>, and three (15.8%) had <jats:styled-content style=\"fixed-case\">PD<\/jats:styled-content>. The five patients with <jats:styled-content style=\"fixed-case\">PR<\/jats:styled-content> were all treated by using crizotinib. Time to progression was 8.2\u00a0months with first\u2010line chemotherapy, and 6.0\u00a0months with second\u2010line chemotherapy. Advanced\u2010stage <jats:italic><jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content><\/jats:italic>\u2010positive tumors have a relatively aggressive phenotype, which cannot be inferred from the size of the tumor alone. <jats:italic><jats:styled-content style=\"fixed-case\">ALK<\/jats:styled-content><\/jats:italic>\u2010positive patients have a good response to first\u2010line cytotoxic drugs and to crizotinib as second\u2010line therapy, but a relatively poor response to cytotoxic drugs as second\u2010line therapy.<\/jats:p>","DOI":"10.1002\/cam4.172","type":"journal-article","created":{"date-parts":[[2013,12,27]],"date-time":"2013-12-27T11:44:55Z","timestamp":1388144695000},"page":"118-123","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Anaplastic lymphoma kinase gene rearrangements in patients with advanced\u2010stage non\u2010small\u2010cell lung cancer: <scp>CT<\/scp> characteristics and response to chemotherapy"],"prefix":"10.1002","volume":"3","author":[{"given":"Jangchul","family":"Park","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Yamaura","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waki","family":"Hosoda","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitsugu","family":"Horio","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimihide","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyo","family":"Oguri","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoaki","family":"Hida","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya 464\u20108681 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,12,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6993"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.04.002"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70344-3"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2012.03.013"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00024"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1018"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0168"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27411"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.04.015"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2203001701"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2003.08.048"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.172","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.172","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.172","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:48:06Z","timestamp":1694998086000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,27]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1002\/cam4.172"],"URL":"https:\/\/doi.org\/10.1002\/cam4.172","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,27]]},"assertion":[{"value":"2013-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-11-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}